AI-generated summary
This retrospective chart review of 56 patients with Fitzpatrick skin types IV to VI, treated with a 755-nm picosecond laser with a diffractive lens array, reports that transient adverse events, mainly erythema and hyperpigmentation, resolved in all cases. The authors state the device may be a safe alternative for scars, pigmented lesions, and striae. The retrospective design is a stated limitation.
- Participants
- 56
- Who or what was studied
- Patients with Fitzpatrick skin types IV to VI with atrophic or hypertrophic scars, pigmented lesions, or striae
- Wavelengths
- 755 nm
- Limits stated in the abstract
- The retrospective design is a limitation, and 10 of 56 patients (17.9%) were lost to follow-up.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.